Our experts
Leadership team
Our goal is to deliver an outstanding customer experience through our passion for ion channel drug discovery. We are focused on quality and attention to detail. We seek out and act upon feedback, enabling us to continue to improve as a company.
The Metrion Biosciences Management Team have extensive, varied and proven ion channel expertise. This includes academic training in leading international labs such as Trinity, UCL, Imperial, Cambridge, Baylor, UCSF, and Yale.
They have together over 100 years of accumulated manual and automated patch clamp experience and are named inventors on over 30 composition of matter patents.
Cumulatively, the team has been awarded over £10M in ion channel R&D grants (UK, EU) and has an impressive and extensive industry drug discovery and development track record. Successful delivery of discovery, preclinical and clinical stage ion channel modulators.
Their broad range of experience at UK, EU, and US biotech, CRO, and pharma companies, including AstraZeneca, BioFocus/Charles River Discovery, Exelixis, Ionix, Merck, NeuroSolutions, Parke Davis, Pfizer, Wyeth, and Xention this gives them a unique perspective on the requirements of the drug discovery market.
Andrew Southan PhD
Chief Executive Officer
Rob Kirby PhD
Chief Operating Officer
Gary Clark PhD
Director, Screening Technologies
Eddy Stevens PhD
Chief Scientific Officer
Tony Rush PhD
Director, Neuroscience
Andrew Lightfoot PhD
Head of Medicinal Chemistry and Discovery Funding
Clare Rutty
Director of Finance and Company Secretary
John Ridley PhD
Director of Commercial Operations
Sophie Rose PhD
Head of Business Development, Europe
Let’s work together
What are your specific ion channel and assay needs?
If you have any questions or would like to discuss your specific assay requirements, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.